BAMF
VIVO

BI Asset Management Fondsmaeglerselskab’s Meridian Bioscience Inc VIVO Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,917
Closed -$180K – 503
2022
Q2 		$180K Buy
+5,917
New +$160K 0.01% 416

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's VIVO Position: Q3 2022 in Review

BI Asset Management Fondsmaeglerselskab sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 5,917 shares — an estimated $180K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in VIVO in Q2 2022 and held it in 1 quarter. The position peaked at $180K in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 5,917 Meridian Bioscience Inc shares in Q3 2022, an estimated $180K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Meridian Bioscience Inc in Q2 2022 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Meridian Bioscience Inc position peaked at $180K in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q3 2022, filed 7 Nov 2022.